BioSpace News Archive

Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched with $128 million in financing.

Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical

Aanastra, Inc. announced poster presentations at the 2024 American Association for Cancer Research, taking place April 5-10, 2024, in San Diego, CA.

Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European Patent Office (EPO) for a new patent covering VAZKEPA® (icosapent ethyl) that will extend VAZKEPA exclusivity eight additional years into 2039.

YS Biopharma Co., Ltd. today announced the full repayment of the US$40,000,000 loan borrowed under that certain facility agreement, dated March 16, 2022, between YishengBio (Hong Kong) Holdings Limited, a wholly-owned subsidiary of the Company, and R-Bridge Healthcare Fund, LP, as agent (the “Facility Agreement”).

PixCell Medical is pleased to announce a strategic distribution partnership with Medline, adding to the partnership agreements with Henry Schein and Thermo Fisher Scientific signed in recent months.

Verismo Therapeutics today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its Phase 1 clinical trial of SynKIR™-310, for the treatment of relapsed/refractory (r/r) B-cell Non-Hodgkin Lymphomas (B-cell NHL), including Diffuse Large B Cell lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL).

Agilent Technologies Inc. announced today its participation in the American Association for Cancer Research Annual Meeting (AACR).

Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate.

iOmx Therapeutics AG announces that it will present new data on its lead I/O drug candidates OMX-0407 and IOMX-0675, plus its proprietary iOTarg™ screening platform at the upcoming American Association for Cancer Research Annual Meeting 2024 taking place from April 5-10, 2024, in San Diego, California.